Summit Therapeutics (SMMT) jumped 5.04% in a technical rebound with buyers capitalizing on deeply oversold momentum and an intraday shift toward session highs. The up move looks limited, with the ...
Summit Therapeutics has signed an agreement to sell its Phase III asset Ridinilazole to Biossil, Inc., according to Summit Therapeutics.The announcement was posted on social media. Details are ...
Summit Therapeutics (SMMT) stock is trading at $14.57, up 1.75% for the day. The stock sits above its key moving averages in the short and medium term, reflecting a ...
Summit Therapeutics said the U.S. FDA has accepted its Biologics License Application seeking approval for ivonescimab in combination with chemotherapy in the treatment of patients with EGFRm NSCLC ...